<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Extended release <z:chebi fb="0" ids="8708">quetiapine fumarate</z:chebi> (<z:chebi fb="0" ids="8707">quetiapine</z:chebi> XR) was initiated at the recommended maximum dose 800 mg and maintained at the same dose in five patients with <z:hpo ids='HP_0100753'>schizophrenia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Although the loadings of <z:chebi fb="0" ids="8707">quetiapine</z:chebi> XR were well tolerated in four patients in these five cases, one patient with a history of <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarction</z:e> developed serious side-effects, notably bladder distention and dizziness </plain></SENT>
<SENT sid="2" pm="."><plain>This case series indicates that loading with maximum dose <z:chebi fb="0" ids="8707">quetiapine</z:chebi> XR may be tolerable and used safely in most <z:hpo ids='HP_0100753'>schizophrenia</z:hpo> patients with no other concurrent disease such as <z:e sem="disease" ids="C0751955" disease_type="Disease or Syndrome" abbrv="">brain infarction</z:e> </plain></SENT>
</text></document>